Craig E. Cole

2.4k total citations
48 papers, 1.1k citations indexed

About

Craig E. Cole is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Craig E. Cole has authored 48 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Hematology, 18 papers in Oncology and 16 papers in Molecular Biology. Recurrent topics in Craig E. Cole's work include Multiple Myeloma Research and Treatments (36 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Lymphoma Diagnosis and Treatment (9 papers). Craig E. Cole is often cited by papers focused on Multiple Myeloma Research and Treatments (36 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Lymphoma Diagnosis and Treatment (9 papers). Craig E. Cole collaborates with scholars based in United States, Canada and Greece. Craig E. Cole's co-authors include Dennis Pietronigro, Glen R. Justice, Annette Ervin‐Haynes, Peter H. Wiernik, Kenichi Takeshita, Julie M. Vose, Jerome B. Zeldis, Thomas M. Habermann, Kenton Wride and Kyle McBride and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Craig E. Cole

45 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Craig E. Cole United States	14	539	497	447	433	321	48	1.1k
Mirosław Majewski Poland	16	456 0.8×	308 0.6×	353 0.8×	522 1.2×	279 0.9×	28	1.4k
Alicja Gruszka Italy	20	259 0.5×	274 0.6×	380 0.9×	395 0.9×	378 1.2×	36	945
Unn‐Merete Fagerli Norway	13	278 0.5×	261 0.5×	201 0.4×	286 0.7×	138 0.4×	33	744
Dixie‐Lee Esseltine United States	11	817 1.5×	1.1k 2.2×	190 0.4×	1.2k 2.8×	285 0.9×	12	1.8k
Marek Hus Poland	17	319 0.6×	461 0.9×	87 0.2×	366 0.8×	239 0.7×	110	869
Daniel Heintel Austria	13	205 0.4×	322 0.6×	289 0.6×	442 1.0×	346 1.1×	30	846
J. Garcia‐Vargas United States	13	495 0.9×	169 0.3×	199 0.4×	503 1.2×	154 0.5×	62	1.2k
Joanna Góra‐Tybor Poland	18	218 0.4×	594 1.2×	381 0.9×	291 0.7×	733 2.3×	82	1.2k
Elber S. Camacho United States	11	474 0.9×	440 0.9×	210 0.5×	444 1.0×	202 0.6×	24	929
J M Connors Canada	11	392 0.7×	130 0.3×	559 1.3×	209 0.5×	285 0.9×	16	946

Countries citing papers authored by Craig E. Cole

Since Specialization

Citations

This map shows the geographic impact of Craig E. Cole's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Craig E. Cole with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Craig E. Cole more than expected).

Fields of papers citing papers by Craig E. Cole

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Craig E. Cole. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Craig E. Cole. The network helps show where Craig E. Cole may publish in the future.

Co-authorship network of co-authors of Craig E. Cole

This figure shows the co-authorship network connecting the top 25 collaborators of Craig E. Cole. A scholar is included among the top collaborators of Craig E. Cole based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Craig E. Cole. Craig E. Cole is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gay, Francesca, Elena Zamagni, Craig E. Cole, et al.. (2025). Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review. Frontiers in Oncology. 15. 1550644–1550644.

Banerjee, Rahul, et al.. (2024). Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel. Blood Cancer Journal. 14(1). 149–149. 7 indexed citations

Diedrich, Jonathan D., Craig E. Cole, Matthew J. Pianko, Justin A. Colacino, & Jamie J. Bernard. (2023). Non-Toxicological Role of Aryl Hydrocarbon Receptor in Obesity-Associated Multiple Myeloma Cell Growth and Survival. Cancers. 15(21). 5255–5255.

Derman, Benjamin A., Jeffrey A. Zonder, Donna Reece, et al.. (2023). Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma. Blood Advances. 7(19). 5703–5712. 3 indexed citations

Cole, Craig E., et al.. (2023). Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24(1). 32–39. 3 indexed citations

Bhutani, Manisha, Brandon Blue, Craig E. Cole, et al.. (2023). Addressing the disparities: the approach to the African American patient with multiple myeloma. Blood Cancer Journal. 13(1). 189–189. 17 indexed citations

Auclair, Daniel, Carol Mansfield, Mark A. Fiala, et al.. (2022). Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States. SHILAP Revista de lepidopterología. 9 indexed citations

Mıkhael, Joseph, Manisha Bhutani, & Craig E. Cole. (2022). Multiple Myeloma for the Primary Care Provider: A Practical Review to Promote Earlier Diagnosis Among Diverse Populations. The American Journal of Medicine. 136(1). 33–41. 20 indexed citations

Mıkhael, Joseph, Joshua Richter, Ravi Vij, et al.. (2020). A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. Leukemia. 34(12). 3298–3309. 37 indexed citations

10.

Jakubowiak, Andrzej, Jagoda Jasielec, Cara A. Rosenbaum, et al.. (2019). Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. British Journal of Haematology. 186(4). 549–560. 55 indexed citations

11.

Auclair, Daniel, Carol Mansfield, Ajai Chari, et al.. (2017). Understanding the Preferences of Patients and Caregivers for Relapsed/Refractory Multiple Myeloma Treatment: A Mixed-Mode Patient-Centric Approach. Blood. 130. 5662–5662. 2 indexed citations

12.

Cho, Hearn Jay, Craig E. Cole, Thomas G. Martin, et al.. (2017). A phase Ib study of atezolizumab (atezo) alone or in combination with lenalidomide or pomalidomide and/or daratumumab in patients (pts) with multiple myeloma (MM).. Journal of Clinical Oncology. 35(15_suppl). TPS8053–TPS8053. 3 indexed citations

13.

Jagannath, Sundar, Jesús G. Berdeja, Robert M. Rifkin, et al.. (2017). Single-Arm, Phase 2 Study of Elotuzumab in Combination With Pomalidomide and Dexamethasone in Patients With Multiple Myeloma Who Are Relapsed/Refractory to Lenalidomide: Initial Safety Data. Clinical Lymphoma Myeloma & Leukemia. 17(1). e127–e127. 3 indexed citations

14.

Martin, Thomas G., Joshua Richter, Ravi Vij, et al.. (2015). A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma. Blood. 126(23). 509–509. 26 indexed citations

15.

Wiernik, Peter H., Izidore S. Lossos, Joseph M. Tuscano, et al.. (2008). Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma. Journal of Clinical Oncology. 26(30). 4952–4957. 300 indexed citations

16.

Go, Ronald S., Dean A. Jobe, Steven M. Callister, et al.. (2008). Circulating endothelial cells in patients with chronic lymphocytic leukemia. Annals of Hematology. 87(5). 369–373. 8 indexed citations

17.

Witzig, Thomas E., Julie M. Vose, Timothy D. Moore, et al.. (2007). Results from a Phase II Study of Lenalidomide Oral Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma.. Blood. 110(11). 2560–2560. 2 indexed citations

18.

Wiernik, Peter H., Izidore S. Lossos, Joseph M. Tuscano, et al.. (2007). Lenalidomide Response in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma Is Related to Tumor Burden and Time from Rituximab Treatment.. Blood. 110(11). 2565–2565. 4 indexed citations

19.

Podar, Klaus, Yu‐Tzu Tai, Craig E. Cole, et al.. (2003). Essential Role of Caveolae in Interleukin-6- and Insulin-like Growth Factor I-triggered Akt-1-mediated Survival of Multiple Myeloma Cells. Journal of Biological Chemistry. 278(8). 5794–5801. 120 indexed citations

20.

Ryoo, Joan J., Craig E. Cole, & Kenneth C. Anderson. (2002). Novel therapies for multiple myeloma. Blood Reviews. 16(3). 167–174. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact